HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

Key Terms

arrhythmia medical

An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.

extended-wear patch medical

An extended-wear patch is a thin, adhesive medical patch designed to be worn on the skin for days to weeks to deliver a steady dose of a drug or monitor a health signal without frequent replacement. Think of it like a slow-release bandage that keeps medication steady or continuously collects data. Investors watch these products for their potential to improve patient adherence, lower healthcare costs, simplify treatment, and create recurring sales and regulatory hurdles or advantages.

ai technical

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call.

HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period.

The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:		Wednesday, May 13, 2026
Time:		4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:		1-877-704-4453
International Dial-in:		1-201-389-0920
Conference Code:		13760379
Webcast:		https://viavid.webcasts.com/starthere.jsp?ei=1761581&tp_key=a64f57a332

A telephone replay will be available approximately three hours after the call and will run through May 27, 2026, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13760379. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025¹. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

¹Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

MKT-140 v0

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430142939/en/

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Media Contact:
media@heartbeam.com

Source: HeartBeam, Inc.